Status:

COMPLETED

Role of Montelukast in Preventing Relapse in Childhood Idiopathic Nephrotic Syndrome

Lead Sponsor:

Nishtar Medical University

Conditions:

Nephrotic Syndrome

Eligibility:

All Genders

1-10 years

Phase:

NA

Brief Summary

The investigators planned this research to elucidate if there is any efficacy of montelukast, a leukotriene receptor antagonist, in steroid sensitive childhood onset NS to help prevent relapses. This ...

Detailed Description

A quasi-experimental study, done at Department of Pediatric Nephrology at the Children's Hospital \& the Institute of Child Health, Multan. A total of 96 patients aged 1-10 years with steroid sensitiv...

Eligibility Criteria

Inclusion

  • A total of 106 children aged 1-10 years with idiopathic nephrotic syndrome were enrolled
  • \-

Exclusion

  • Patients having Steroid resistant nephrotic syndrome (SRNS) or those having nephrotic syndrome with atypical features or Secondary cause were excluded.

Key Trial Info

Start Date :

February 1 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 30 2020

Estimated Enrollment :

106 Patients enrolled

Trial Details

Trial ID

NCT04818723

Start Date

February 1 2019

End Date

May 30 2020

Last Update

March 26 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Department of Pediatric Nephrology, The Children's Hospital and Institute of Child Health

Multan, PPunjab, Pakistan

Role of Montelukast in Preventing Relapse in Childhood Idiopathic Nephrotic Syndrome | DecenTrialz